时间标签：数据日期 2026-11-05 · 生成时间 2026-11-05 05:30（Asia/Shanghai）｜ 检索窗口 PubMed edat 2026/11/02 – 2026/11/06 ｜ 情报发生日期 2026-11-05
研究问题
（原文未给出可直接抽取的对应表述）
方法
However, data on the longevity of the humoral response remain limited.2Materials and methods2.1Participants and serum samplesIn August 2025, we enrolled two individuals who had laboratory-confirmed CHIKV infection during an outbreak in 2017 in Quzhou City, Zhejiang Province, China.；We included serum samples from four individuals in our laboratory repository who had received the inactivated coronavirus disease 2019 (COVID-19) vaccine and no documented history of dengue or chikungunya virus infection as negative controls.2.2Cell lines and virusHEK-293T cells (ATCC, CRL-3216) and Vero cells (ATCC, CCL-81) were authenticated at the source, as noted in the Certificate of Analysis provided by the vendor, and the cell lines were confirmed to be mycoplasma negative.；HEK-293T and Vero cells were propagated at 37°C with 5% CO2 in Dulbecco’s Modified Eagle’s Medium (DMEM, Gibco) supplemented with 10% (v/v) heat-inactivated fetal bovine serum (FBS, Gibco) and 1% penicillin‒streptomycin (Gibco).
核心结论
These findings also directly support the prospect that an effective CHIKV vaccine may provide long-term protection, potentially reducing the need for frequent booster vaccinations.；Finally, the scope of this work did not include evaluating the neutralization breadth against other CHIKV genotypes, which is important for comprehensively understanding long-term immunity against infection.5ConclusionsIn summary, this study provides important data indicating that a single CHIKV infection elicits a potent and long-lasting neutralizing antibody response.；These findings strengthen the rationale for developing vaccination strategies to achieve durable protection against CHIKV infection.Ethics statementThe study protocol was approved by the Institutional Review Board of the Academy of Military Medical Sciences (IRB number: AF/SC-08/02.60).
局限
However, such persistence may be attributed to subsequent exposure to circulating CHIKV strains.；However, data on the longevity of the humoral response remain limited.2Materials and methods2.1Participants and serum samplesIn August 2025, we enrolled two individuals who had laboratory-confirmed CHIKV infection during an outbreak in 2017 in Quzhou City, Zhejiang Province, China.；Notably, this study was conducted in a non-endemic setting without previous and subsequent outbreaks of CHIKV, in contrast to studies from endemic regions, which strengthens the evidence that robust and durable neutralizing antibodies observed after a single infection were unlikely to be the result of repeated antigenic boosting through reinfection or recurrent exposure; however, subclinical infection cannot be completely ruled out.
对本项目的价值
中等价值：属「衰老机制与老年临床」方向；其他衰老相关栏目可用作本项目文献库与综述素材。 ｜ 价值分 2.6/5（★★★☆☆）
全文来源
PubMed PMC JATS（正文 15,307 字符，题名指纹 1.0，已过 PubMed PMCID 官方关联 + 题名指纹 + 正文长度归属校验）
原文题录
- 中文题名：基孔肯雅病毒感染八年后中和抗体仍持续存在
- 英文标题：Persistent neutralizing antibodies against chikungunya virus eight years after infection.
- 期刊与标识：Biosafety and health · PMID 42979312 · DOI 10.1016/j.bsheal.2026.07.005 · PMC PMC13729069